Sangamo (SGMO) Posts Wider than Expected Q1 Loss
Sangamo Biosciences Inc. (Nasdaq: SGMO) reported Q1 loss of $0.21, $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $4.09 million.